NCT02647281 - First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

January 3, 2017

Study Completion Date

January 3, 2017

Conditions

Hepatitis B

Interventions

DRUG

GSK3389404

GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.

DRUG

Matching Placebo

Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.

Trial Locations (2)

NW10 7EW

GSK Investigational Site, London

SE1 1YR

GSK Investigational Site, London